14P Gut and oral microbiota profiling in patients (pts) with hormone receptor-positive (HR+) metastatic breast cancer (MBC) receiving pembrolizumab (P) plus eribulin (E): CALADRIO
| Autor: | Teng, N., Dalby, M.J., Kiu, R., Robinson, T., Gion Cortes, M., Bermejo De Las Heras, B., Perez Garcia, J.M., Calvo-Martinez, L., Prat, A., Marquez Vazquez, R., Ruiz Borrego, M., de la Cruz, S., Llombart Cussac, A., Curigliano, G., Schmid, P., Mancino, M., Hall, L., Robinson, S., Cortés, J., Malfettone, A. |
|---|---|
| Zdroj: | In Annals of Oncology May 2022 33 Supplement 3:S129-S130 |
| Databáze: | ScienceDirect |
| Externí odkaz: |
|